NCT06057467

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate Acute Ischemic Stroke Patients With Non-valvular Atrial Fibrillation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,351 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF). Participants will be 1:1 randomized into early or late initiation group. The primary endpoint is early neurological deterioration (END) before discharge.

Detailed description

Anticoagulation therapy is effective to prevent ischemic stroke in patients with NVAF who have a history of stroke. Recent clinical trials have demonstrated that early initiation of anticoagulation therapy after AIS is safe, while no remarkable benefits have been observed. The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in AIS patients with non-NVAF. Participants will be 1:1 randomized into early or late initiation group. The primary endpoint is END before discharge.

Conditions

• Acute Ischemic Stroke
• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	Anticoagulation Agents	Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.

Timeline

• Start date: 2023-09-15
• Primary completion: 2025-10-01
• Completion: 2026-01-01
• First posted: 2023-09-28
• Last updated: 2024-03-18

Locations

2 sites across 1 country: China